Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a drug stop dangerous side effects of new myeloma therapies?

NCT ID NCT07657312

Recruiting now Disease control Sponsor: Naresh Bumma Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 09, 2026 · Updated 3 times

Summary

This phase 2 trial tests whether infliximab, a drug that blocks inflammation, can prevent cytokine release syndrome (CRS) in people with relapsed or refractory multiple myeloma receiving teclistamab or talquetamab. CRS is a common and sometimes serious side effect of these treatments. The study will enroll 35 adults who have already tried at least four prior therapies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
infliximab
What this could lead to
If successful, this could provide a way to prevent severe side effects from newer myeloma treatments, making them safer and more tolerable.
What could go wrong
This is a small early-phase trial with only 35 participants, so results may not apply broadly. Infliximab itself can cause infections or allergic reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CYTOKINE RELEASE SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma refractory plasma cell neoplasm cytokine release syndrome prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CYTOKINE RELEASE SYNDROME RECURRENT MULTIPLE MYELOMA REFRACTORY MULTIPLE MYELOMA

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Ohio State University Comprehensive Cancer Center

    RECRUITING

    Columbus, Ohio, 43210, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.